Overview

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Status:
Active, not recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib